CTLA4 and cancer: With the successful implementation of immune checkpoint inhibitors, such as those targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor 1 (PD-1), immunotherapy has become a pivotal cornerstone in the realm of cancer treatment (1–3).